Prodia Subsidiary Launches Stem Cell Therapy in Partnership with Atma Jaya Hospital
Main Takeaways
|
JAKARTA, Investortrust.id — PT Prodia StemCell Indonesia has signed a strategic partnership with Atma Jaya Hospital to provide certified stem cell therapy services in Jakarta, marking a new milestone in Indonesia’s biotechnology sector.
The agreement, formalized on Tuesday, July 9, 2025, at RS Atma Jaya in Pluit, North Jakarta, will enable the development of research-based regenerative therapies. The hospital is now the first private academic medical institution in North Jakarta to receive certification from the Ministry of Health to provide stem cell treatment.
PT Prodia StemCell Indonesia (ProSTEM) is a subsidiary of PT Prodia Widyahusada Tbk (PRDA), a leading diagnostics and life sciences company in Indonesia. The collaboration aims to advance stem cell applications in clinical practice and broaden access to innovative therapies for degenerative conditions.
Medical Innovation Meets Certified Practice
Cynthia Retna Sartika, President Director of ProSTEM, said the initiative is rooted in a shared commitment to deliver scientifically validated, internationally benchmarked regenerative solutions.
“We welcome this partnership with RS Atma Jaya as it supports our mission to offer safe, GMP-standard stem cell therapies, underpinned by robust internal quality control systems,” said Cynthia in a written statement on Wednesday, July 30.
Atma Jaya’s director, Maria Theresia Yulita, emphasized the hospital’s dedication to innovation grounded in science.
“As the teaching hospital of Atma Jaya Catholic University’s Faculty of Medicine and Health Sciences, we are committed to driving health innovation and serving the wider public with advanced, evidence-based care,” she said.
Comprehensive Regenerative Platform
ProSTEM is equipped with ISO 9001:2015-certified manufacturing capabilities and operates as a Contract Development and Manufacturing Organization (CDMO). The company offers end-to-end stem cell therapy services — from sample collection to delivery — supported by a transparent, integrated quality control framework and an active research publication track record.
RS Atma Jaya was selected as a clinical partner due to its strong service reputation, quality oversight, and skilled human resources. Together, the institutions will jointly develop regenerative health programs, including clinical trials for degenerative diseases, medical training initiatives, public education on biotechnology, and business model development for sustainable stem cell services.
Discover biotech investment insights and stay ahead in regenerative medicine trends with InvestingPro. Get an exclusive discount for Investortrust readers — click here to access the offer.